| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1cd7029ec038fa78d4b371f9bf08e9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7c6696bedbca295dbe66b766cc5a149
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f0b88141bcae3cf170a3bdfec7c0a5d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02ffbeca18cdb143770643ba24f912c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43b75bef3762d24511f7c1e86d227554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3fefdb1826b2428ecc2ab59164f9348 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
2009-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd28517c737f265902f663ae4ae1be53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_576a349b0c45dbde727b338f1fd7f06f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4531332095fd442aa30e736d4f02d683
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0f70e7674e0bd1888e5939aee431214
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daf669f1cd74a9b97869975d5de275aa |
| publicationDate |
2010-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010022143-A2 |
| titleOfInvention |
Assessing and treating breast cancer patients |
| abstract |
This document provides methods and materials related to assessing and treating breast cancer patients. For example, methods and materials that involve assessing a breast cancer patient to determine whether the patient has (1) cancer cells that over express HER-2 polypeptides or comprise a HER-2 amplification and (2) at least an intermediate CYP2D6 metabolizer status are provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110075097-A |
| priorityDate |
2008-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |